Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.

In this prospective study (NCT01595295), 272 patients treated with azacitidine completed 1456 EuroQol 5-Dimension (EQ-5D) questionnaires. Linear mixed-effect modelling was used to incorporate longitudinal data. When compared with a matched reference population, myeloid patients reported more pronounced restrictions in usual activities (+28%, < 0.0001), anxiety/depression (+21%, < 0.0001), selfcare (+18%, < 0.0001) and mobility (+15%, < 0.0001), as well as lower mean EQ-5D-5L indices (0.81 vs. 0.88, < 0.0001), and lower self-rated health on the EuroQol Visual Analogue Scale (EQ-VAS) (64 vs. 72%, < 0.0001). After multivariate-adjustment, (i) the EQ-5D-5L index assessed at azacitidine start the predicted time with clinical benefit (TCB) (9.6 vs. 6.6 months; = 0.0258; HR = 1.43), time to next treatment (TTNT) (12.8 vs. 9.8 months; = 0.0332; HR = 1.42) and overall survival (OS) (17.9 vs. 12.9 months; = 0.0143; HR = 1.52); (ii) Level Sum Score (LSS) predicted azacitidine response ( = 0.0160; OR = 0.451) and the EQ-5D-5L index showed a trend ( = 0.0627; OR = 0.522); (iii) up to 1432 longitudinally assessed EQ-5D-5L response/clinical parameter pairs revealed significant associations of EQ-5D-5L response parameters with haemoglobin level, transfusion dependence and hematologic improvement. Significant increases of the likelihood ratios were observed after addition of LSS, EQ-VAS or EQ-5D-5L-index to the International Prognostic Scoring System (IPSS) or the revised IPSS (R-IPSS), indicating that they provide added value to these scores.

PMID: 36900181